Dazodalibep

达佐利贝普

Report date: 2026/03/31 20:00:21

Base Information

Drug NameDazodalibep
Drug Alias NameVIB-4920MEDI-4920HZN-4920(Horizon Therapeutics)UNII-HN5US76BWFWHO-11399
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionCD40 ligand inhibitors
TargetsCD40 ligand
Therapy Area/IndicationsRejection of renal transplantationGraft RejectionSjogren-Larsson Syndrome +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[29] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesMedimmune LlcHorizon Therapeutics PLC
China Registration ClassN/A

Develop Information

Active CompaniesAmgen IncNational Institute Of Allergy And Infectious Diseases (Niaid)
Inactive CompaniesViela Bio IncMedimmune LlcMedimmune Pharma Bv
Active IndicationsRejection of renal transplantationGraft RejectionSjogren-Larsson Syndrome +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A